CO FENTANYL PATCH

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

FENTANYL

Доступна з:

COBALT PHARMACEUTICALS COMPANY

Код атс:

N02AB03

ІПН (Міжнародна Ім'я):

FENTANYL

Дозування:

25MCG

Фармацевтична форма:

PATCH

Склад:

FENTANYL 25MCG

Адміністрація маршрут:

TRANSDERMAL

Одиниць в упаковці:

5

Тип рецепту:

Narcotic (CDSA I)

Терапевтична области:

OPIATE AGONISTS

Огляд продуктів:

Active ingredient group (AIG) number: 0123302014; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2018-05-17

Характеристики продукта

_ _
_CO _FENTANYL_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
N
_CO_ FENTANYL
Fentanyl Transdermal Patches (Matrix)
12 mcg/h
25 mcg/h
37 mcg/h
50 mcg/h
75 mcg/h
100 mcg/h
Opioid Analgesic
Cobalt Pharmaceuticals Company
Date of Revision:
6733 Mississauga Road, Suite 400
August 23, 2017
Mississauga, Ontario
L5N 6J5
Submission Control No.: 208560
_ _
_CO _FENTANYL_ _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS
AND
PRECAUTIONS
...........................................................................................
5
ADVERSE
REACTIONS
..........................................................................................................
14
DRUG
INTERACTIONS
...........................................................................................................
17
DOSAGE
AND
ADMINISTRATION
.......................................................................................
18
OVERDOSAGE
.........................................................................................................................
25
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
26
STORAGE
AND
STABILITY...................................................................................................
28
SPECIAL
HANDLING
INSTRUCTIONS
................................................................................
29
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 29
PART II: SCIENTIFIC INFORMATION
................................................................................
31
PHARMACE